This webpage presents data on COVID-19 cases with information on pregnancy status reported to CDC. COVID-19 is a nationally notifiable disease and reporting cases to CDC is supported by routine case notification through the National Notifiable Diseases Surveillance System (NNDSS), as well as resources provided through the CDC COVID-19 response.

As of March 2022, CDC no longer recommends universal case investigation and contact tracing and recommends that health department jurisdictions prioritize specific settings and groups at increased risk. In addition, a decreasing number of case reports include information on pregnancy status. For these reasons CDC will stop reporting data on this page on July 19th, 2022.

Information about findings from this data and about CDC’s ongoing data collection efforts to better understand the impact of COVID-19 during pregnancy can be found here.

In March 2022, CDC changed its data collection schedule to every 8 weeks for the nationwide COVID-19 infection-induced antibody seroprevalence (commercial laboratory) survey. It now includes information on antibodies for pediatric age groups (ages 6 months to 17 years). Adult antibody updates will be based on the national blood donor seroprevalence study.

This dashboard, which includes information for all age groups, has been updated through February 2022. Updated pediatric seroprevalence information from March 2022 is available here. CDC currently plans to end the nationwide SARS-CoV-2 antibody studies in December 2022.

From May 31, 2022 forward, data on this page will be updated on a quarterly basis. Due to unforeseen delays, data for quarter 1 has been delayed and it is unknown at this time when the data will be made available. The National Blood Donor Seroprevalence Survey concluded monthly data collection in December 2021. This study is being modified and estimates will cover 3-month periods. CDC currently plans to end nationwide seroprevalence studies in December 2022.